JW THERAP-B

2126
2.4957.42% ( -0.200 )
Delay Closed: Nov 16, 16:08:11

Overview

JW THERAP-B (2126)

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunot...

Open
3.095
High
3.095
Low
2.420
Prev. Close
2.695
Volume
9.32M
Turnover
25.67M
Avg Price
2.753
Bid/Ask Ratio
50.00%
Amplitude
25.05%
52wk High
3.710
Volume Ratio
16.13
Turnover Ratio
2.24%
52wk Low
1.400
HK Mkt Cap
1.04B
Market CapHKD
1.04B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.935
EPSDynamic
-0.279
EPSStatic
--
BVPS
1.25
P/B
2.00
HK Shares
416.88M
Dividend YieldTTM
--
DividendTTM
--
Shares
416.88M
Min lot size
500
Currency
HKD

JW THERAP-B Analyst Rating

View more

Forecast & Rating

Sep 3, 2025
Price forecast
HK$6.04142.20%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    JW Therapeutics opened at HK$3.095 and sold off from an early HK$3.035 print at 09:39 BJ to HK$2.420 at 11:06 BJ, closing at HK$2.490, down 7.6% from HK$2.695 on 9.32 million shares and HK$25.66 million turnover, as the 13% move tied to Carteyva's 2026 NRDL inclusion and guidance for a more than 65% cut in unit manufacturing costs gave way to profit-taking. The operating trend still shows narrowing losses: Q2 2026 revenue rose 10.37% year on year to HK$64.31 million, net loss narrowed 80.11% to HK$29.12 million and EPS improved 80.16% to -HK$0.0699, though operating loss was HK$53.68 million. A HK$160 million placement and a US$10 million upfront payment from the Eureka licensed-asset transfer add financing and portfolio items. The close sits above MA20 of HK$2.45 and MA60 of HK$2.405, but remains 33.42% below the 52-week high of HK$3.74 and down 0.4% YTD. Though PB is 1.99 and market cap is HK$1.038 billion, the negative PE of -2.66 leaves valuation dependent on a future volume ramp.

  2. Nov, 13

    JW Therapeutics-B staged a spike-and-fade session: the lift tied to its hepatocellular carcinoma TCR-T licensing deal stalled at an intraday high of HK$2.870 at 10:41 BJ, then slid to HK$2.675 at 15:19 and closed at HK$2.710, below the full-day average of HK$2.735 and 5.6% off the peak, on 2.819 million shares and a 0.67% turnover rate. That transaction transfers licensed assets to Eureka for a US$10 million upfront payment and had lifted the stock roughly 6% on the announcement, but after a 12.61% gain the prior week, profit-taking pressure around HK$2.87 was evident. Market capitalisation is HK$1.124 billion at a 2.16x price-to-book with a negative price-to-earnings ratio, consistent with continuing losses. Though, with turnover of only HK$7.71 million, the thin tape amplified the intraday swing.

  3. Nov, 12

    JW Therapeutics (2126.HK) opened weak but climbed through the session and closed at HK$2.700, up 5.06%, after agreeing to transfer its licensed hepatocellular carcinoma TCR-T assets to Eureka for a US$10 million upfront payment. It dipped to HK$2.545 at 09:38 BJ, hit HK$2.775 at 14:11 BJ, then eased into the close on 2.229 million shares and HK$5.99 million turnover, a thin 0.53% turnover rate. The price sits above MA20 of HK$2.452 and MA60 of HK$2.379, up 8% year-to-date, yet remains 27.81% below the 52-week high of HK$3.74 (12 Nov 2025) and 92.86% above the HK$1.40 low of 21 June. Q2 2026 revenue was HK$64.3 million, up 10.37% year on year, while the net loss narrowed 80.11% to HK$29.1 million, leaving net margin at -45.28%, PB at 2.16 and PE negative. Though the US$10 million upfront is modest against a HK$1.126 billion market cap, and losses persist.

  4. Nov, 10

    JW Therapeutics reversed an opening spike and regained ground, closing at HK$2.605 against a HK$2.505 prior close, up about 4.0%, after touching HK$2.675 at the 09:30 BJ open, sliding to HK$2.505 by 10:08 and recovering to HK$2.650 in the afternoon session on 882,500 shares. The trigger was the transfer of its liver-cancer TCR-T program rights to Eureka Hong Kong with a licence grant, bringing a US$10 million upfront payment while the company expects a US$2.1 million loss on disposal. Q2 2026 revenue was HK$64.3 million, up 10.37% year on year, and the net loss narrowed 80.11% to HK$29.1 million, though the net margin remains -45.28%. The stock sits above MA20 of HK$2.467 and MA60 of HK$2.355, up 4.2% year to date yet still 37.68% below the 52-week high of HK$4.18, with PB at 2.08x. Turnover rate was only 0.21%, while the disposal itself carries that US$2.1 million loss.

  5. Nov, 6

    JW Therapeutics opened at HK$2.55 and faded, closing at HK$2.50 for a 6.02% decline on thin turnover of HK$1.35 million from 538,000 shares, a 0.13% turnover rate, with the pullback following gains of 6% and 12% in the prior two sessions. The morning session slid from a HK$2.595 high to HK$2.470 by 11:33, and an afternoon bounce to HK$2.570 faded into the close. Q2 2026 revenue was HK$64.31 million, up 10.37% year on year, and the net loss narrowed 80.11% to HK$29.12 million, though the net margin of -45.28% and ROE of -22.29% remain negative, alongside a 2.00x price-to-book and HK$1.04 billion market value. At HK$2.50 the stock sits on its 20-day average, flat year to date, 40.19% below the 52-week high of HK$4.18 while 78.57% above the HK$1.40 low. While CAR-T reimbursement inclusion and a recovering Hong Kong biotech licensing backdrop remain medium-term items to watch.

News